Sell-off rumours circle AZ

 Posted December 7, 2021 PM

AstraZeneca is the latest big pharma said to be considering carving off part of its business into a separate entity, with the company's newly formed COVID-19 vaccine and antibody treatment unit tipped as ripe to spin out on its own.

Just last month the company set up the new division which would take control of the company's vaccine Vaxzevrvia and its long acting antibody Evusheld as well as several other respiratory infection treatments.

To see the whole article, please login